NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free ARDX Stock Alerts $6.49 -0.20 (-2.99%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$6.40▼$6.7550-Day Range$6.31▼$9.3152-Week Range$3.16▼$10.13Volume3.14 million shsAverage Volume5.71 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$12.81 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside97.4% Upside$12.81 Price TargetShort InterestHealthy13.30% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.92Based on 10 Articles This WeekInsider TradingSelling Shares$4.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to $0.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector98th out of 917 stocksPharmaceutical Preparations Industry33rd out of 431 stocks 4.6 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArdelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ardelyx's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.30% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Ardelyx has recently decreased by 6.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 2.2 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ardelyx this week, compared to 5 articles on an average week.Search InterestOnly 29 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,318,649.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.36) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 9.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesJune 8, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Insider Sells $1,032,400.00 in StockJune 6, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 17,872 Shares of StockJune 1, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 7,500 Shares of StockMay 16, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 3,000 Shares of StockJune 9, 2024 | americanbankingnews.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 145,000 Shares of StockJune 8, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Down 5.5% After Insider SellingJune 7, 2024 | americanbankingnews.comDavid P. Rosenbaum Sells 17,872 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockJune 7, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Upgraded at StockNews.comJune 4, 2024 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Short Interest UpdateMay 30, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMay 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 24, 2024 | msn.comArdelyx slips as commercial chief departsMay 22, 2024 | benzinga.comLatest News for Ardelyx Stock (NASDAQ:ARDX)May 22, 2024 | globenewswire.comArdelyx to Participate at the 2024 Jefferies Global Healthcare ConferenceMay 21, 2024 | globenewswire.comArdelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsMay 19, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in May 2024May 16, 2024 | globenewswire.comArdelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)May 15, 2024 | msn.comArdelyx (NASDAQ:ARDX): A Commercial-Stage Biopharma Stock with Growth PotentialMay 14, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMay 10, 2024 | seekingalpha.comArdelyx: Strong Execution, Fairly ValuedMay 7, 2024 | globenewswire.comArdelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week ConferenceMay 4, 2024 | finance.yahoo.comArdelyx First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call TranscriptMay 3, 2024 | seekingalpha.comArdelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)May 3, 2024 | marketwatch.comArdelyx Shares Rally Premarket as 1Q Revenue Tops Street ViewsSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$12.81 High Stock Price Target$15.00 Low Stock Price Target$8.50 Potential Upside/Downside+97.4%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-41.36% Pretax Margin-40.95% Return on Equity-41.65% Return on Assets-23.08% Debt Debt-to-Equity Ratio0.66 Current Ratio4.53 Quick Ratio4.36 Sales & Book Value Annual Sales$124.46 million Price / Sales12.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book9.01Miscellaneous Outstanding Shares232,700,000Free Float219,902,000Market Cap$1.51 billion OptionableOptionable Beta0.79 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMOPKO HealthNASDAQ:OPK89bioNASDAQ:ETNBFlexion TherapeuticsNASDAQ:FLXNXBiotechNASDAQ:XBITView All CompetitorsInsiders & InstitutionsLaura A WilliamsSold 145,000 sharesTotal: $1.03 M ($7.12/share)David P RosenbaumSold 17,872 sharesTotal: $125,104.00 ($7.00/share)Michael RaabSold 7,500 sharesTotal: $50,400.00 ($6.72/share)Farallon Capital Management LLCBought 23,000 shares on 5/24/2024Ownership: 0.010%Virtu Financial LLCBought 30,087 shares on 5/20/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price target for 2024? 9 analysts have issued 1-year target prices for Ardelyx's shares. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's share price to reach $12.81 in the next twelve months. This suggests a possible upside of 97.4% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2024? Ardelyx's stock was trading at $6.20 on January 1st, 2024. Since then, ARDX shares have increased by 4.7% and is now trading at $6.49. View the best growth stocks for 2024 here. Are investors shorting Ardelyx? Ardelyx saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 30,940,000 shares, a decrease of 6.4% from the May 15th total of 33,040,000 shares. Based on an average daily volume of 5,200,000 shares, the days-to-cover ratio is presently 6.0 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The biopharmaceutical company had revenue of $46 million for the quarter, compared to analysts' expectations of $36.40 million. Ardelyx had a negative net margin of 41.36% and a negative trailing twelve-month return on equity of 41.65%. The firm's revenue for the quarter was up 303.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Biotech ETF (XBI).First Trust Small Cap Growth AlphaDEX Fund (FYC). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). Who are Ardelyx's major shareholders? Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.47%), Vanguard Group Inc. (5.72%), Price T Rowe Associates Inc. MD (1.68%), Redmile Group LLC (0.94%), Jane Street Group LLC (0.00%) and BNP Paribas Financial Markets (0.25%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.